Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: EHP
Latest Price: 400.00p  (0,00%)
52-week High: 422.50p
52-week Low: 347.50p
Market Cap: 35.40M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Epistem Holdings Plc
www.epistem.co.uk

Epistem is a biotechnology company commercialising adult stem cells in the areas of oncology and gastrointestinal diseases as well as cosmeceutical applications. Epistem develops innovative therapeutics and diagnostic biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.

Pdf

Epistem wins UK Trade & Investment award for expansion success

14th Dec 2009, 12:53 pm Epistem wins UK Trade & Investment award for expansion success

Epistem Holdings PLC (AIM: EHP), a UK biotechnology company with adult epithelial stem cell expertise in oncology, gastrointestinal and dermatological diseases, has won a national award for its overseas success, The Manchester Evening News reported on its website.

Epistem, which announced in October plans to open an office in the US, received the UK Trade & Investment's 'Internationalise Your Business' accolade at the Genesis 2009 biotechnology conference in London.

The UK government’s international business development organisation presents the award to the company the UKTI judges to have been the most successful at expanding into new markets following assistance from the organisation.

Epistem, led by chief executive Matthew Walls, beat candidate drug discovery services group BioFocus DPI, contract manufacturer Eden Biodesign, plant and marine extract specialist Neem Biotech and voice recognition group Winscribe Europe to the title.

The firm, which posted its maiden annual profits in October, has made progress working with pharmaceutical companies in Canada, Europe, Japan and Australia as well as the US, the report said.

Epistem's activities include testing drugs under development for treating cancer, Crohn's disease and other illnesses, analysing the effects of treatments by examining the cells at the base of a single human hair, and identifying genes that regulate cell growth.

In November, Epistem raised £2.9 million via a shares placing to bolster its balance sheet and provide money for acquisitions.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.